Skip to main content

Table 4 Relation between HCC recurrence and different parameters in group I

From: Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence

 HCC recurrenceTest of Sig.p
No (n = 31), no. (%)Yes (n = 19), no. (%)
BCLC
 05 (16.1%)0 (0.0%)χ2 = 0.161*0.004*
 A21 (67.7%)8 (42.1%)
 B5 (16.1%)11 (57.9%)
HCC treatment
 Hepatic resection5 (16.1%)6 (31.5%)χ2 = 4.989*p = 0.035*
 RFA16 (51.6%)11 (57.8%)χ2 = 0.693p = 0.405
 LDLT8 (25.8%)2 (10.5%)χ2 = 5.837*p = 0.018*
 Alcohol injection2 (6.4%)0 (0.0%)χ2 = 0.625p = 1.000
HCV treatment (weeks)
 Min.–Max.12.0–24.012.0–24.0t = 1.2020.238
 Mean ± SD13.94 ± 4.4915.79 ± 5.73
 Median12.012.0
HCV treatment
 SOF/DAC1 (3.2%)0 (0.0%)χ2 = 0.625p = 1.000
 SOF/DAC/RBV17 (54.8%)13 (68.4%)χ2 = 0.905p = 0.341
 SOF/LED3 (9.7%)2 (10.5%)χ2 = 0.009p = 1.000
 SOF/LED/RBV0 (0.0%)1 (5.3%)χ2 = 1.665p = 0.380
 SOF/RBV6 (19.4%)3 (15.8%)χ2 = 0.101p = 1.000
 SOF/SIM4 (12.9%)0 (0.0%)χ2 = 2.665p = 0.284
PCR after TTT
 SVR29 (93.5%)13 (68.4%)χ2 = 5.534*p = 0.041*
 Relapser2 (6.5%)6 (31.6%)
  1. SOF sofosbuvir, LED ledipasvir, RBV ribavirin, SIM simeprevir, DAC daclatasvir, SVR sustained virological response